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OBJECTIVES: Little is known about variations in resource use and cost of stroke 
among patients experiencing stroke at different age. Recent observation of getting 
younger among stroke patients in Korea raises a concern on the loss of labor forces. 
Thus, this study was conducted to compare per-person lifetime cost of stroke accord-
ing to the age of stroke onset from the Korea societal perspective. METHODS: 
The cost for fatal stroke was measured as one-time cost. The cost for non-fatal stroke 
was estimated as a lifetime cost using Markov cohort simulation. Then, weighted 
average cost was calculated based on the proportion of fatal or non-fatal stroke among 
Korean population. Transition probabilities were derived from published sources. 
Average cost for fatal stroke and 1st- and 2nd-year of non-fatal stroke was estimated 
from the National Health Insurance claims records. RESULTS: The lifetime economic 
impact of stroke is 10.6^ 4.5 times higher for men aged 45 or 55 (196.6^83.7 million 
Korean won) than those 65 (8.2 million KW). Women experiencing stroke at 45 or 
55 (69.5 or 38.1 million KW) showed 3.2^1.8 times higher lifetime cost than women 
at 65 (21.1 million KW). While stroke from those aged 45^64 accounted for only 
20% of incidence, the total national lifetime costs of stroke was explained by 72% 
from this age group. CONCLUSIONS: Higher lifetime burden and increasing inci-
dence of stroke among younger population in Korea suggests that more effective 
strategy targeting young population should be adopted to prevent stroke incidence in 
the nation.
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WESTERN AND ORIENTAL MEDICAL TREATMENT IN SOUTH KOREA
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OBJECTIVES: In Korea, not only has the number of stroke patients increased, but 
also the integrated western and oriental medical treatment became popular. In this 
study, treatment costs for stroke were compared for those with integrated treatment 
with the costs of western treatment. METHODS: During the period between May 
2006 and February 2009, the treatment cost was analyzed for 318 stroke patients 
who were admitted to the emergency room of a secondary hospital. Medical records 
were collected and detailed cost items were compared. SAS Version 9.1 was used for 
data analysis. RESULTS: The estimated annual treatment cost for a stroke patient is 
KRW 10.55 million for the integrated treatment, whereas it is KRW 8.11 for western 
treatment only. The biggest parts of integrated treatment cost were for rehabilitation 
and oriental medical treatments. Because much of oriental treatments is not covered 
by health insurance, patients’ burden were heavier compared to western treatment. 
Oriental treatment comprises 16.3% for the inpatients, whereas higher at 65.2% for 
outpatients. In addition, although the incidence of ischemic stroke was higher than 
that of hemorrhagic stroke, the average days of hospitalization and average total 
treatment cost per patient were higher in the case of hemorrhagic stroke in Korea. 
CONCLUSIONS: The integrated medical treatment costs more than only the western 
treatment. However, more detailed study with more integrated treatment patients will 
be needed to generalize the study results.
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OBJECTIVES: Hypertension, hyperglycemia and hyperlipidemia (HHH) are impor-
tant health problems due to their relationship with cardiovascular, cerebrovascular 
and peripheral vascular diseases. Previous studies have found that individuals with 
HHH were associated with more health care resource use, yet no study has been con-
ducted in Taiwan to estimate the cost impact of HHH on society. This study aimed 
to determine the incremental costs among the individuals with HHH, compared with 
no symptom individuals in Taiwan with no symptons. METHODS: A retrospective 
case-control analysis was performed using a unique dataset that linked the 2002 
 Taiwanese Survey on Prevalence of Hypertension, Hyperglycemia and Hyperlipidemia 
(TwSHHH) with the 2003–2006 National Health Insurance (NHI) claims records. 
Study cases were 1277 individuals with hypertension, 409 individuals with hypergly-
cemia, and 1808 individuals in Taiwan with hyperlipidemia. For each symptom group, 
controls without symptoms were matched at a 1:3 ratio by demographics. The differ-
ence in medical costs between cases and controls was assumed to be attributable to 
HHH. Negative binomial regression based on generalized estimating equations were 
performed to compute regression-adjusted annual total medical costs. All costs were 
reported in NT dollars (US$1.00  NT$34.42 in 2003). RESULTS: Adjusted mean 
annual number of outpatient visits for HHH were 5.81, 11.62 and 4.36, respectively. 
Mean annual number of hospital days for HHH were 1.67, 3.13 and 0.97, respec-
tively. Mean annual drug costs for HHH were NT$8,612, NT$ 14,665, and NT$ 
3,578, respectively. Mean annual total medical costs for HHH were NT$21,117, NT$ 
34,853, and NT$ 9,678, respectively. CONCLUSIONS: This study demonstrated a 
substantial increase in resource usage in terms of the frequency of care use and medical 
costs associated with HHH. Indirect morbidity costs need to be estimated in the future 
to provide the information on the overall economic burden of HHH to policy-makers 
in Taiwan.
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OBJECTIVES: Orthopaedic surgery is one of the highest risk factors for venous 
thromboembolism.The main objective of this retrospective database analysis was to          
determine direct medical costs for pulmonary embolism (PE) in patient undergoing 
orthopaedic surgery in Slovakia from the payer perspective. METHODS: A retrospec-
tive database analysis of biggest health insurance company in Slovakia was conducted. 
Resources used and their respective costs in connection with PE were collected for 
patients undergoing elective total hip replacement (THR) or elective total knee repla-
cement (TKR) during the period from January 1, 2007 till January 1, 2008. All 
resources and costs were categorized in four groups: inpatient, outpatient, drugs and 
examinations. Costs in Euro were calculated with ofﬁcial exchange rate 30,126 Sk/a. 
Cost comparison between groups of patients with PE and without PE after orthopaedic 
surgery was done. RESULTS: The group of 3069 patients (1121 men and 1948 
women) after elective orthopaedic surgery was analyzed. There were 2153 patients 
with THR and 916 with TKR. The average age was 64.5 and 68.4 years in THR and 
in TKR group respectively. Eighteen cases of PE were identiﬁed in the whole group 
(11 in THR and 7 in TKR). Average direct medical costs for group of patients were 
a5964 with PE and a3170 without PE. There was a following structure of costs (WITH         
and WITHOUT pulmonary embolism): 1) inpatient: a5064 and a2516; 2) outpatient: 
a171 and a141; 3) drugs: a339 and a251; and 4) examinations: a390 and a262. 
CONCLUSIONS: Average direct medical costs for patients with PE after elective ort-
hopedic surgery are a5964. This is almost 90% more then the average direct medical 
costs for patients without PE. Main driver of increased costs is inpatient stay at 
intensive care unit and at internal medicine department after episode of pulmonary 
embolism.
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OBJECTIVES: Atrial Fibrillation (AF) is an important public health problem. The aim 
of the study is to assess the costs of AF in the German health care system. METHODS: 
From a payer’s perspective we determined annual direct medical costs of patients with 
paroxysmal, persistent and permanent AF based on 2008 prices. Cost calculation is 
based on a bottom-up approach. Resource items (e.g. laboratory tests) and quantity 
of resource use were identiﬁed by literature research and by consulting medical 
experts. Prices for outpatient treatment and drugs were obtained from ofﬁcial cata-
logues considering prices. Inpatient treatment was priced by use of the German Diag-
nosis Related Groups System. Costs were calculated in a cost database by relating 
resource use and corresponding price. Appropriate discounts and rebates were taken 
into consideration. RESULTS: The annual average aggregated costs of paroxysmal AF 
are a1394, of persistent AF are a2130 and of permanent AF are a1073 without the 
costs for diagnostic investigations. Including these costs there are a1644 for paroxys-
mal AF and a2441 for persistent AF. Permanent AF is not considered, because patients 
are not diagnosed as permanent by the ﬁrst doctor’s contact. From payer’s perspective, 
the main cost driver was hospitalization (a756 to 1809), especially due to the proce-
dures of electrical cardioversion. CONCLUSIONS: The cost evaluation shows that 
AF is related with high costs for the social health insurance in Germany. Because the 
data used are predominantly taken from publications, it might not reﬂect the real 
resource use for Germany. In the same way data raised by experts opinion do not 
reﬂect a generally applicable resource use. Despite these limitations the present study 
shows valid data of costs for AF in Germany. Our results are comparable with the 
results of another German cost-of-illness-analyses and the results of the German 
Competence Network on AF.
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OBJECTIVES: Diabetes is an independent prognostic factor for increased risk for 
ischemic heart disease. This study evaluates differences in health care costs and 
resource utilization for acute coronary syndrome (ACS) patients with and without 
diabetes mellitus (DM). METHODS: A retrospective cohort study was conducted 
using a large US administrative claims database. Patients aged 18–65 years hospital-
ized with a primary diagnosis of ACS between January 1, 2005 and December 31, 
